Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$82.26 +2.0%	$82.81	$57.52 ▼ $93.25	$31.62B	1.43	4.01 million shs	3.67 million shs
GMED Globus Medical	$62.54 +3.4%	$57.30	$51.79 ▼ $94.93	$8.17B	1.2	1.49 million shs	719,357 shs
PODD Insulet	$330.77 +0.9%	$300.94	$180.31 ▼ $334.18	$23.08B	1.35	705,185 shs	499,504 shs
STE STERIS	$251.73 +1.7%	$234.96	$200.98 ▼ $252.79	$24.38B	0.92	556,042 shs	375,557 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	+2.03%	+1.62%	-4.82%	-2.66%	+12.38%
GMED Globus Medical	+3.39%	+3.16%	+15.65%	+6.01%	-10.14%
PODD Insulet	+0.89%	+2.96%	+15.38%	+2.93%	+78.02%
STE STERIS	+1.82%	+2.53%	+11.53%	+3.50%	+7.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.8406 of 5 stars	3.5	4.0	0.0	4.7	3.5	2.5	1.9
GMED Globus Medical	4.9456 of 5 stars	4.3	3.0	0.0	4.1	2.4	2.5	3.1
PODD Insulet	4.3651 of 5 stars	2.4	5.0	0.0	4.9	2.8	0.0	1.9
STE STERIS	4.2177 of 5 stars	1.4	3.0	3.3	3.8	3.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$99.89	21.44% Upside
GMED Globus Medical	2.62	Moderate Buy	$87.64	40.12% Upside
PODD Insulet	2.89	Moderate Buy	$332.71	0.59% Upside
STE STERIS	2.75	Moderate Buy	$273.50	8.65% Upside

Current Analyst Ratings Breakdown

Latest GMED, DXCM, STE, and PODD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DXCM DexCom	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00
8/21/2025	PODD Insulet	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$266.00 ➝ $300.00
8/8/2025	GMED Globus Medical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$76.00 ➝ $66.00
8/8/2025	PODD Insulet	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$331.00 ➝ $353.00
8/8/2025	PODD Insulet	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$330.00 ➝ $350.00
8/8/2025	PODD Insulet	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$330.00 ➝ $350.00
8/8/2025	STE STERIS	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$276.00 ➝ $295.00
8/7/2025	PODD Insulet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
8/7/2025	PODD Insulet	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/1/2025	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
7/31/2025	DXCM DexCom	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	8.00	$2.29 per share	35.87	$6.56 per share	12.54
GMED Globus Medical	$2.52B	3.35	$6.88 per share	9.09	$31.81 per share	1.97
PODD Insulet	$2.07B	11.24	$4.48 per share	73.90	$20.78 per share	15.92
STE STERIS	$5.46B	4.54	$14.50 per share	17.36	$70.77 per share	3.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.44	57.13	33.44	1.69	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
GMED Globus Medical	$102.98M	$2.60	24.06	15.52	1.69	13.58%	10.65%	8.86%	11/4/2025 (Estimated)
PODD Insulet	$418.30M	$3.29	100.54	66.55	2.75	10.01%	23.78%	9.30%	11/6/2025 (Estimated)
STE STERIS	$614.64M	$6.53	38.55	25.35	N/A	11.61%	14.17%	9.25%	11/5/2025 (Estimated)

Latest GMED, DXCM, STE, and PODD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMED Globus Medical	$0.76	$0.86	+$0.10	$1.50	$738.91 million	$745.34 million
8/7/2025	Q2 2025	PODD Insulet	$0.92	$1.17	+$0.25	$0.32	$612.31 million	$649.10 million
8/6/2025	Q1 2026	STE STERIS	$2.32	$2.34	+$0.02	$1.79	$1.36 billion	$1.40 billion
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
PODD Insulet	N/A	N/A	N/A	N/A	N/A
STE STERIS	$2.28	0.91%	N/A	34.92%	20 Years

Latest GMED, DXCM, STE, and PODD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	STE STERIS	quarterly	$0.63	1.1%	9/4/2025	9/4/2025	9/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.48	1.52	1.35
GMED Globus Medical	N/A	4.07	2.26
PODD Insulet	0.64	2.26	1.81
STE STERIS	0.27	2.22	1.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
GMED Globus Medical	95.16%
PODD Insulet	N/A
STE STERIS	94.69%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
GMED Globus Medical	18.51%
PODD Insulet	0.39%
STE STERIS	1.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
GMED Globus Medical	5,300	135.06 million	110.06 million	Optionable
PODD Insulet	3,900	70.39 million	70.12 million	Optionable
STE STERIS	17,787	98.49 million	97.44 million	Optionable

GMED, DXCM, STE, and PODD Headlines

Recent News About These Companies

Is STERIS Set for More Growth After Recent 10% Rally in 2025?

August 22 at 8:22 AM | finance.yahoo.com

Aspire Growth Partners LLC Purchases Shares of 2,435 STERIS plc $STE

August 22 at 6:57 AM | marketbeat.com

GDS Wealth Management Has $14.24 Million Stake in STERIS plc $STE

August 22 at 6:39 AM | marketbeat.com

Fox Run Management L.L.C. Acquires Shares of 1,465 STERIS plc $STE

August 22 at 3:57 AM | marketbeat.com

Steward Partners Investment Advisory LLC Has $7.22 Million Holdings in STERIS plc $STE

August 21 at 4:42 AM | marketbeat.com

Aberdeen Group plc Sells 180,689 Shares of STERIS plc $STE

August 21 at 4:17 AM | marketbeat.com

Dimensional Fund Advisors LP Has $208.51 Million Holdings in STERIS plc $STE

August 21 at 4:17 AM | marketbeat.com

Granite Harbor Advisors Inc. Takes Position in STERIS plc $STE

August 20 at 7:09 AM | marketbeat.com

State of New Jersey Common Pension Fund D Lowers Holdings in STERIS plc $STE

August 20 at 6:04 AM | marketbeat.com

American Century Companies Inc. Grows Stake in STERIS plc $STE

August 20 at 5:43 AM | marketbeat.com

Steris PLC stock underperforms Tuesday when compared to competitors despite daily gains

August 19, 2025 | marketwatch.com

Raymond James Financial Inc. Acquires 11,428 Shares of STERIS plc (NYSE:STE)

August 19, 2025 | marketbeat.com

Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Position in STERIS plc (NYSE:STE)

August 19, 2025 | marketbeat.com

STERIS plc $STE Shares Sold by Russell Investments Group Ltd.

August 19, 2025 | marketbeat.com

Tracking Al Gore's Generation Investment Management Portfolio - Q2 2025 Update

August 18, 2025 | seekingalpha.com

STERIS plc (NYSE:STE) Stock Holdings Cut by Gulf International Bank UK Ltd

August 18, 2025 | marketbeat.com

National Pension Service Buys 12,057 Shares of STERIS plc (NYSE:STE)

August 18, 2025 | marketbeat.com

Steris: Marginal Gains Capitalized At Higher Rates, Reiterate Buy

August 17, 2025 | seekingalpha.com

STERIS plc (NYSE:STE) Shares Sold by Kimelman & Baird LLC

August 17, 2025 | marketbeat.com

Neuberger Berman Group LLC Boosts Stake in STERIS plc (NYSE:STE)

August 17, 2025 | marketbeat.com

OneAscent Investment Solutions LLC Takes $673,000 Position in STERIS plc (NYSE:STE)

August 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GMED, DXCM, STE, and PODD Company Descriptions

DexCom NASDAQ:DXCM

$82.26 +1.64 (+2.03%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$82.14 -0.12 (-0.15%)

As of 08/22/2025 07:32 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Globus Medical NYSE:GMED

$62.54 +2.04 (+3.38%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$62.54 -0.01 (-0.01%)

As of 08/22/2025 06:30 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Insulet NASDAQ:PODD

$330.77 +2.92 (+0.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$330.52 -0.25 (-0.08%)

As of 08/22/2025 07:14 PM Eastern

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

STERIS NYSE:STE

$251.73 +4.23 (+1.71%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$251.92 +0.18 (+0.07%)

As of 08/22/2025 04:16 PM Eastern

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time